|
|
drug_name
|
event_name
|
drug_id
|
event_id
|
drug_and_event_name
|
|
2
|
Glucose
|
Disorder of lung
|
1560524
|
257907
|
Glucose & Disorder of lung
|
## Chronograph ##
## Basic demographic table##
|
|
1: DEC cohort
|
n
|
Percentage
|
|
2: Drug cohort
|
n
|
Percentage
|
|
3: Event cohort
|
n
|
Percentage
|
|
4: All drugs cohort
|
n
|
Percentage
|
|
|
Total
|
304
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
1000
|
100
|
|
Sex
|
gender = FEMALE
|
181
|
60
|
Sex
|
gender = FEMALE
|
587
|
59
|
Sex
|
gender = FEMALE
|
584
|
58
|
Sex
|
gender = FEMALE
|
546
|
55
|
|
|
gender = MALE
|
123
|
40
|
|
gender = MALE
|
413
|
41
|
|
gender = MALE
|
416
|
42
|
|
gender = MALE
|
454
|
45
|
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
|
|
(20,30]
|
2
|
1
|
|
(20,30]
|
7
|
1
|
|
(20,30]
|
6
|
1
|
|
(20,30]
|
6
|
1
|
|
|
(30,40]
|
7
|
2
|
|
(30,40]
|
21
|
2
|
|
(30,40]
|
17
|
2
|
|
(30,40]
|
14
|
1
|
|
|
(40,50]
|
9
|
3
|
|
(40,50]
|
45
|
4
|
|
(40,50]
|
32
|
3
|
|
(40,50]
|
45
|
4
|
|
|
(50,60]
|
13
|
4
|
|
(50,60]
|
72
|
7
|
|
(50,60]
|
73
|
7
|
|
(50,60]
|
56
|
6
|
|
|
(60,70]
|
65
|
21
|
|
(60,70]
|
221
|
22
|
|
(60,70]
|
200
|
20
|
|
(60,70]
|
224
|
22
|
|
|
(70,80]
|
102
|
34
|
|
(70,80]
|
348
|
35
|
|
(70,80]
|
346
|
35
|
|
(70,80]
|
391
|
39
|
|
|
(80,90]
|
83
|
27
|
|
(80,90]
|
225
|
22
|
|
(80,90]
|
259
|
26
|
|
(80,90]
|
218
|
22
|
|
|
(90,110]
|
23
|
8
|
|
(90,110]
|
61
|
6
|
|
(90,110]
|
67
|
7
|
|
(90,110]
|
46
|
5
|
|
|
Median
|
77
|
IQR=(69, 84)
|
|
Median
|
74
|
IQR=(68, 82)
|
|
Median
|
75
|
IQR=(68, 83)
|
|
Median
|
74
|
IQR=(68, 81)
|
## Gender distribution ##
## DEC vs. drug ##
|
Characteristic
|
% (n = 304)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 304)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
3.6
|
0.6
|
-0.21
|
|
25 - 29
|
0.7
|
0.7
|
0.01
|
Visual system disorder
|
53.0
|
35.5
|
-0.36
|
|
30 - 34
|
0.3
|
0.4
|
0.01
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.6
|
1.5
|
-0.01
|
Atrial fibrillation
|
42.4
|
27.9
|
-0.31
|
|
40 - 44
|
1.0
|
1.5
|
0.05
|
Cerebrovascular disease
|
18.8
|
11.0
|
-0.22
|
|
45 - 49
|
2.0
|
2.8
|
0.05
|
Coronary arteriosclerosis
|
50.0
|
32.3
|
-0.37
|
|
50 - 54
|
1.6
|
2.9
|
0.08
|
Heart disease
|
83.2
|
60.7
|
-0.52
|
|
55 - 59
|
1.6
|
3.9
|
0.14
|
Heart failure
|
43.1
|
28.0
|
-0.32
|
|
60 - 64
|
4.9
|
3.4
|
-0.08
|
Ischemic heart disease
|
24.3
|
16.1
|
-0.21
|
|
65 - 69
|
13.5
|
16.2
|
0.08
|
Peripheral vascular disease
|
45.7
|
28.6
|
-0.36
|
|
70 - 74
|
17.1
|
19.3
|
0.06
|
Pulmonary embolism
|
6.9
|
3.5
|
-0.15
|
|
75 - 79
|
16.1
|
16.1
|
0.00
|
Venous thrombosis
|
13.5
|
7.7
|
-0.19
|
|
80 - 84
|
17.8
|
13.3
|
-0.12
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
12.5
|
10.0
|
-0.08
|
Hematologic neoplasm
|
17.1
|
10.8
|
-0.18
|
|
90 - 94
|
4.6
|
5.1
|
0.02
|
Malignant lymphoma
|
8.6
|
4.8
|
-0.15
|
|
95 - 99
|
3.6
|
2.1
|
-0.09
|
Malignant neoplasm of anorectum
|
3.3
|
2.3
|
-0.06
|
|
100 - 104
|
1.0
|
0.8
|
-0.02
|
Malignant neoplastic disease
|
42.1
|
29.3
|
-0.27
|
|
Gender: female
|
59.5
|
58.7
|
-0.02
|
Malignant tumor of breast
|
7.9
|
5.5
|
-0.10
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
9.5
|
5.3
|
-0.16
|
|
Acute respiratory disease
|
39.8
|
23.0
|
-0.37
|
Malignant tumor of urinary bladder
|
5.6
|
2.8
|
-0.14
|
|
Attention deficit hyperactivity disorder
|
0.3
|
0.1
|
-0.05
|
Medication use
|
|
|
|
|
Chronic liver disease
|
5.6
|
1.3
|
-0.24
|
Agents acting on the renin-angiotensin system
|
67.1
|
69.6
|
0.05
|
|
Chronic obstructive lung disease
|
12.5
|
7.5
|
-0.17
|
Antibacterials for systemic use
|
51.6
|
51.1
|
-0.01
|
|
Crohn’s disease
|
1.0
|
1.1
|
0.01
|
Antidepressants
|
65.5
|
62.2
|
-0.07
|
|
Dementia
|
20.1
|
14.4
|
-0.15
|
Antiepileptics
|
37.8
|
38.2
|
0.01
|
|
Depressive disorder
|
16.8
|
11.3
|
-0.16
|
Antiinflammatory and antirheumatic products
|
33.6
|
35.5
|
0.04
|
|
Diabetes mellitus
|
74.7
|
54.4
|
-0.43
|
Antineoplastic agents
|
22.7
|
13.2
|
-0.25
|
|
Gastroesophageal reflux disease
|
26.6
|
14.6
|
-0.30
|
Antipsoriatics
|
0.7
|
0.4
|
-0.04
|
|
Gastrointestinal hemorrhage
|
10.5
|
6.6
|
-0.14
|
Antithrombotic agents
|
63.2
|
49.1
|
-0.29
|
|
Human immunodeficiency virus infection
|
0.3
|
0.8
|
0.06
|
Beta blocking agents
|
61.8
|
63.6
|
0.04
|
|
Hyperlipidemia
|
33.2
|
25.8
|
-0.16
|
Calcium channel blockers
|
50.0
|
56.8
|
0.14
|
|
Hypertensive disorder
|
8.2
|
4.5
|
-0.15
|
Diuretics
|
69.7
|
67.6
|
-0.05
|
|
Lesion of liver
|
5.6
|
3.2
|
-0.12
|
Drugs for acid related disorders
|
55.3
|
47.9
|
-0.15
|
|
Obesity
|
10.5
|
5.9
|
-0.17
|
Drugs for obstructive airway diseases
|
47.0
|
37.6
|
-0.19
|
|
Osteoarthritis
|
53.6
|
36.0
|
-0.36
|
Drugs used in diabetes
|
60.5
|
62.6
|
0.04
|
|
Psoriasis
|
2.3
|
1.4
|
-0.07
|
Immunosuppressants
|
6.9
|
3.7
|
-0.14
|
|
Renal impairment
|
39.5
|
26.6
|
-0.28
|
Lipid modifying agents
|
69.7
|
72.6
|
0.06
|
|
Rheumatoid arthritis
|
8.9
|
6.3
|
-0.10
|
Opioids
|
42.8
|
33.6
|
-0.19
|
|
Schizophrenia
|
10.5
|
6.6
|
-0.14
|
Psycholeptics
|
60.9
|
52.9
|
-0.16
|
|
Ulcerative colitis
|
0.7
|
0.2
|
-0.07
|
Psychostimulants, agents used for adhd and nootropics
|
14.1
|
14.2
|
0.00
|
|
Urinary tract infectious disease
|
34.5
|
20.7
|
-0.31
|
|
|
|
|
## Event vs. All ##
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
2.1
|
1.8
|
-0.02
|
|
25 - 29
|
0.4
|
0.6
|
0.03
|
Visual system disorder
|
50.2
|
38.1
|
-0.25
|
|
30 - 34
|
0.7
|
1.0
|
0.03
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.1
|
0.2
|
-0.11
|
Atrial fibrillation
|
43.1
|
28.1
|
-0.32
|
|
40 - 44
|
1.1
|
0.9
|
-0.02
|
Cerebrovascular disease
|
15.8
|
9.5
|
-0.19
|
|
45 - 49
|
2.0
|
3.1
|
0.07
|
Coronary arteriosclerosis
|
48.8
|
27.4
|
-0.45
|
|
50 - 54
|
3.3
|
2.7
|
-0.04
|
Heart disease
|
81.4
|
57.4
|
-0.54
|
|
55 - 59
|
3.7
|
3.0
|
-0.04
|
Heart failure
|
40.9
|
23.5
|
-0.38
|
|
60 - 64
|
3.7
|
2.8
|
-0.05
|
Ischemic heart disease
|
24.8
|
12.7
|
-0.31
|
|
65 - 69
|
13.9
|
15.9
|
0.06
|
Peripheral vascular disease
|
45.4
|
28.5
|
-0.36
|
|
70 - 74
|
17.2
|
22.2
|
0.13
|
Pulmonary embolism
|
5.4
|
2.8
|
-0.13
|
|
75 - 79
|
17.8
|
18.2
|
0.01
|
Venous thrombosis
|
12.8
|
8.3
|
-0.15
|
|
80 - 84
|
15.3
|
13.5
|
-0.05
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
11.4
|
9.9
|
-0.05
|
Hematologic neoplasm
|
16.2
|
7.0
|
-0.29
|
|
90 - 94
|
5.0
|
3.8
|
-0.06
|
Malignant lymphoma
|
7.0
|
3.6
|
-0.15
|
|
95 - 99
|
2.8
|
1.8
|
-0.07
|
Malignant neoplasm of anorectum
|
3.0
|
2.4
|
-0.04
|
|
100 - 104
|
0.6
|
0.4
|
-0.03
|
Malignant neoplastic disease
|
42.9
|
25.1
|
-0.38
|
|
Gender: female
|
58.4
|
54.6
|
-0.08
|
Malignant tumor of breast
|
6.4
|
2.8
|
-0.17
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
6.4
|
4.0
|
-0.11
|
|
Acute respiratory disease
|
34.6
|
21.8
|
-0.29
|
Malignant tumor of urinary bladder
|
4.1
|
2.6
|
-0.08
|
|
Attention deficit hyperactivity disorder
|
0.1
|
0.5
|
0.07
|
Medication use
|
|
|
|
|
Chronic liver disease
|
3.2
|
2.9
|
-0.02
|
Agents acting on the renin-angiotensin system
|
44.6
|
0
|
-1.27
|
|
Chronic obstructive lung disease
|
15.7
|
6.9
|
-0.28
|
Antibacterials for systemic use
|
38.0
|
0
|
-1.11
|
|
Crohn’s disease
|
0.9
|
0.8
|
-0.01
|
Antidepressants
|
42.5
|
0
|
-1.22
|
|
Dementia
|
19.9
|
11.3
|
-0.24
|
Antiepileptics
|
24.5
|
0
|
-0.81
|
|
Depressive disorder
|
13.3
|
8.0
|
-0.17
|
Antiinflammatory and antirheumatic products
|
25.2
|
0
|
-0.82
|
|
Diabetes mellitus
|
71.1
|
50.0
|
-0.44
|
Antineoplastic agents
|
15.7
|
0
|
-0.61
|
|
Gastroesophageal reflux disease
|
24.2
|
13.7
|
-0.27
|
Antipsoriatics
|
0.7
|
0
|
-0.12
|
|
Gastrointestinal hemorrhage
|
11.4
|
6.4
|
-0.18
|
Antithrombotic agents
|
38.1
|
0
|
-1.11
|
|
Human immunodeficiency virus infection
|
1.2
|
0.5
|
-0.08
|
Beta blocking agents
|
42.1
|
0
|
-1.21
|
|
Hyperlipidemia
|
36.7
|
24.9
|
-0.26
|
Calcium channel blockers
|
32.8
|
0
|
-0.99
|
|
Hypertensive disorder
|
5.7
|
4.8
|
-0.04
|
Diuretics
|
45.9
|
0
|
-1.30
|
|
Lesion of liver
|
7.3
|
3.4
|
-0.17
|
Drugs for acid related disorders
|
32.6
|
0
|
-0.98
|
|
Obesity
|
9.0
|
5.0
|
-0.16
|
Drugs for obstructive airway diseases
|
29.4
|
0
|
-0.91
|
|
Osteoarthritis
|
56.1
|
39.1
|
-0.35
|
Drugs used in diabetes
|
36.7
|
0
|
-1.08
|
|
Psoriasis
|
1.6
|
1.8
|
0.02
|
Immunosuppressants
|
4.7
|
0
|
-0.31
|
|
Renal impairment
|
38.4
|
22.0
|
-0.36
|
Lipid modifying agents
|
46.8
|
0
|
-1.33
|
|
Rheumatoid arthritis
|
10.3
|
6.2
|
-0.15
|
Opioids
|
28.6
|
0
|
-0.90
|
|
Schizophrenia
|
7.4
|
3.7
|
-0.16
|
Psycholeptics
|
41.9
|
0
|
-1.20
|
|
Ulcerative colitis
|
0.7
|
0.2
|
-0.07
|
Psychostimulants, agents used for adhd and nootropics
|
11.2
|
0
|
-0.50
|
|
Urinary tract infectious disease
|
33.2
|
17.9
|
-0.36
|
|
|
|
|
## Drug vs. All ##
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
2.1
|
1.8
|
-0.02
|
|
25 - 29
|
0.4
|
0.6
|
0.03
|
Visual system disorder
|
50.2
|
38.1
|
-0.25
|
|
30 - 34
|
0.7
|
1.0
|
0.03
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.1
|
0.2
|
-0.11
|
Atrial fibrillation
|
43.1
|
28.1
|
-0.32
|
|
40 - 44
|
1.1
|
0.9
|
-0.02
|
Cerebrovascular disease
|
15.8
|
9.5
|
-0.19
|
|
45 - 49
|
2.0
|
3.1
|
0.07
|
Coronary arteriosclerosis
|
48.8
|
27.4
|
-0.45
|
|
50 - 54
|
3.3
|
2.7
|
-0.04
|
Heart disease
|
81.4
|
57.4
|
-0.54
|
|
55 - 59
|
3.7
|
3.0
|
-0.04
|
Heart failure
|
40.9
|
23.5
|
-0.38
|
|
60 - 64
|
3.7
|
2.8
|
-0.05
|
Ischemic heart disease
|
24.8
|
12.7
|
-0.31
|
|
65 - 69
|
13.9
|
15.9
|
0.06
|
Peripheral vascular disease
|
45.4
|
28.5
|
-0.36
|
|
70 - 74
|
17.2
|
22.2
|
0.13
|
Pulmonary embolism
|
5.4
|
2.8
|
-0.13
|
|
75 - 79
|
17.8
|
18.2
|
0.01
|
Venous thrombosis
|
12.8
|
8.3
|
-0.15
|
|
80 - 84
|
15.3
|
13.5
|
-0.05
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
11.4
|
9.9
|
-0.05
|
Hematologic neoplasm
|
16.2
|
7.0
|
-0.29
|
|
90 - 94
|
5.0
|
3.8
|
-0.06
|
Malignant lymphoma
|
7.0
|
3.6
|
-0.15
|
|
95 - 99
|
2.8
|
1.8
|
-0.07
|
Malignant neoplasm of anorectum
|
3.0
|
2.4
|
-0.04
|
|
100 - 104
|
0.6
|
0.4
|
-0.03
|
Malignant neoplastic disease
|
42.9
|
25.1
|
-0.38
|
|
Gender: female
|
58.4
|
54.6
|
-0.08
|
Malignant tumor of breast
|
6.4
|
2.8
|
-0.17
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
6.4
|
4.0
|
-0.11
|
|
Acute respiratory disease
|
34.6
|
21.8
|
-0.29
|
Malignant tumor of urinary bladder
|
4.1
|
2.6
|
-0.08
|
|
Attention deficit hyperactivity disorder
|
0.1
|
0.5
|
0.07
|
Medication use
|
|
|
|
|
Chronic liver disease
|
3.2
|
2.9
|
-0.02
|
Agents acting on the renin-angiotensin system
|
44.6
|
0
|
-1.27
|
|
Chronic obstructive lung disease
|
15.7
|
6.9
|
-0.28
|
Antibacterials for systemic use
|
38.0
|
0
|
-1.11
|
|
Crohn’s disease
|
0.9
|
0.8
|
-0.01
|
Antidepressants
|
42.5
|
0
|
-1.22
|
|
Dementia
|
19.9
|
11.3
|
-0.24
|
Antiepileptics
|
24.5
|
0
|
-0.81
|
|
Depressive disorder
|
13.3
|
8.0
|
-0.17
|
Antiinflammatory and antirheumatic products
|
25.2
|
0
|
-0.82
|
|
Diabetes mellitus
|
71.1
|
50.0
|
-0.44
|
Antineoplastic agents
|
15.7
|
0
|
-0.61
|
|
Gastroesophageal reflux disease
|
24.2
|
13.7
|
-0.27
|
Antipsoriatics
|
0.7
|
0
|
-0.12
|
|
Gastrointestinal hemorrhage
|
11.4
|
6.4
|
-0.18
|
Antithrombotic agents
|
38.1
|
0
|
-1.11
|
|
Human immunodeficiency virus infection
|
1.2
|
0.5
|
-0.08
|
Beta blocking agents
|
42.1
|
0
|
-1.21
|
|
Hyperlipidemia
|
36.7
|
24.9
|
-0.26
|
Calcium channel blockers
|
32.8
|
0
|
-0.99
|
|
Hypertensive disorder
|
5.7
|
4.8
|
-0.04
|
Diuretics
|
45.9
|
0
|
-1.30
|
|
Lesion of liver
|
7.3
|
3.4
|
-0.17
|
Drugs for acid related disorders
|
32.6
|
0
|
-0.98
|
|
Obesity
|
9.0
|
5.0
|
-0.16
|
Drugs for obstructive airway diseases
|
29.4
|
0
|
-0.91
|
|
Osteoarthritis
|
56.1
|
39.1
|
-0.35
|
Drugs used in diabetes
|
36.7
|
0
|
-1.08
|
|
Psoriasis
|
1.6
|
1.8
|
0.02
|
Immunosuppressants
|
4.7
|
0
|
-0.31
|
|
Renal impairment
|
38.4
|
22.0
|
-0.36
|
Lipid modifying agents
|
46.8
|
0
|
-1.33
|
|
Rheumatoid arthritis
|
10.3
|
6.2
|
-0.15
|
Opioids
|
28.6
|
0
|
-0.90
|
|
Schizophrenia
|
7.4
|
3.7
|
-0.16
|
Psycholeptics
|
41.9
|
0
|
-1.20
|
|
Ulcerative colitis
|
0.7
|
0.2
|
-0.07
|
Psychostimulants, agents used for adhd and nootropics
|
11.2
|
0
|
-0.50
|
|
Urinary tract infectious disease
|
33.2
|
17.9
|
-0.36
|
|
|
|
|
## Top drugs and conditions for DEC ##
|
drugs_180_days
|
n_180_days
|
|
antithrombotic agents
|
384
|
|
beta blocking agents
|
376
|
|
alimentary tract and metabolism
|
275
|
|
nervous system
|
275
|
|
cardiovascular system
|
272
|
|
all other therapeutic products
|
248
|
|
blood and blood forming organs
|
246
|
|
respiratory system
|
234
|
|
antiepileptics
|
230
|
|
analgesics
|
218
|
|
antihistamines for systemic use
|
214
|
|
ophthalmologicals
|
213
|
|
sensory organs
|
213
|
|
diuretics
|
212
|
|
lipid modifying agents
|
212
|
|
lipid modifying agents, plain
|
212
|
|
psychoanaleptics
|
211
|
|
systemic hormonal preparations, excl. sex hormones and insulins
|
207
|
|
agents acting on the renin-angiotensin system
|
204
|
|
antidepressants
|
199
|
|
hmg coa reductase inhibitors
|
194
|
|
psycholeptics
|
185
|
|
drugs used in diabetes
|
184
|
|
stomatological preparations
|
184
|
|
blood glucose lowering drugs, excl. insulins
|
182
|
|
cond_180_days
|
n_180_days
|
|
heart disease
|
253
|
|
pain
|
251
|
|
pain finding at anatomical site
|
246
|
|
inflammation of specific body systems
|
244
|
|
arthropathy
|
242
|
|
measurement finding outside reference range
|
234
|
|
inflammation of specific body organs
|
233
|
|
vascular disorder
|
228
|
|
diabetes mellitus
|
227
|
|
soft tissue lesion
|
214
|
|
type 2 diabetes mellitus
|
211
|
|
pain of truncal structure
|
197
|
|
abnormal blood cell count
|
186
|
|
measurement finding below reference range
|
183
|
|
structural disorder of heart
|
183
|
|
neoplastic disease
|
178
|
|
cytopenia
|
177
|
|
erythropenia
|
177
|
|
rbc count abnormal
|
177
|
|
rbc count low
|
177
|
|
cardiac arrhythmia
|
176
|
|
hemoglobin level outside reference range
|
176
|
|
hemoglobin low
|
176
|
|
anemia
|
175
|
|
arteriosclerotic vascular disease
|
173
|